Laboratory research reveals how statins inhibit metastasis of some cancers
the ONA take:
Scientists have known that statins sometimes appear to have anticancer activities; however, they were not clear on what the mechanism was. Clinical trials on the use of statins as an anticancer drug have yielded mixed results.
Research from the University of Pittsburgh School of Medicine may have found how this effect works. Statins appear to interfere with the cholesterol synthesis process cancer cells need to reprogram themselves from an adherent state to a mobile state, thereby preventing metastases.
Most cancer deaths are caused by metastases rather than the primary tumor, making the interruption in this process a significant step in improving patient outcomes.
Cancer cell lines that contain the protein vimentin inside the cell, but do not display the protein E-cadherin on their surface, are particularly sensitive to statins. Eventually, clinicians may be able to test biopsy samples for this biomarker to determine if statins would be effective.
Although statins may not effective on their own, adding statins to the treatment of the primary tumor may prevent metastasis, and possibly prevent those cells that break away from surviving or reactivating in other parts of the body.
The researchers stress that these results were seen in a laboratory setting, and the process may work differently in the human body.
Clinical trials on the use of statins as an anticancer drug have yielded mixed results.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|